At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease.
